A type of human leukocyte antigen (HLA) that is associated with the skin disease bullous pemphigoid (BP) has been identified in diabetic patients administered with DPP-4 inhibitory drugs.
DPP-4 inhibitor (DPP-4i) is widely used to treat type 2 diabetes, but increased cases of bullous pemphigoid (BP) have been reported among patients taking the medicine. BP is the most common autoimmune blistering disorder, characterized by itchy reddening of the skin as well as tense blisters over the whole body.
Lifestyle Changes can Prevent Gestational Diabetes: Interview With Gynecologist of Apollo Cradle
Gestational Diabetes (GD) is linked with delivery of pre mature babies. Dr. Vimee Bindra reveals how lifestyle changes can help pregnant women combat the condition.
Advertisement
‘HLA-DQB1*03:01 is not linked to ordinary BP nor type-2 diabetes, but is closely associated with the development of BP among DPP-4i takers.’
Tweet it Now
Afflicted patients - mostly elderly - suffer from autoimmune attacks on a type of collagen in skin, making it hard to cure and compromising their quality of life. Previously, no risk factor triggering BP in diabetic patients administered with DPP-4i had been identified.
Bullous pemphigoid (BP)
BP is classified into two types: inflammatory and noninflammatory, the latter of which is found more in diabetic patients administered with the drug. The research team, including Dr. Hideyuki Ujiie of Hokkaido University Hospital, examined 30 BP patients administered with DPP-4i and investigated their symptoms and autoantibodies to group them as inflammatory or noninflammatory.
![Diabetes Drug Acetohexamide Repairs UV Damaged DNA in Moon Children]( "Diabetes Drug Acetohexamide Repairs UV Damaged DNA in Moon Children")
Moonchildren are referred to those with a genetic disorder that can cause inflammation in response to UV rays and can cause skin cancer.
The researchers then analyzed human leukocyte antigen (HLA) genes of the 30 patients to identify their white blood cell type since HLA genes are known to be involved in various immune diseases. To compare, the team also analyzed the HLA of 72 BP patients who had not been administered to DPP-4i and 61 diabetic patients who were using the drug but not affected by BP. Their findings were compared with the HLA genes of 873 Japanese from the general population.
According to the results, 70 percent of the 30 BP patients administered with DPP-4i fell into the noninflammatory type with less reddening of the skin (erythema). HLA analyses found 86 percent of the noninflammatory BP patients administered with DPP-4i had an HLA gene called "HLA-DQB1*03:01."
The rate of having the HLA gene was much higher than was detected among the general population (18 percent) and non-BP type-2 diabetic patients administered with DPP-4i (31 percent). Meanwhile, 26 percent of BP patients who were not administered with the drug had the same HLA gene.
The findings show HLA-DQB1*03:01 is not linked to ordinary BP nor type-2 diabetes, but is closely associated with the development of BP among DPP-4i takers. "However, as the probability of patients exposed to DPP-4i to develop BP remains unclear, further research investigating a much larger number of cases is needed," says Hideyuki Ujiie.
"Our results suggest people with HLA-DQB1*03:01 have a higher risk of developing BP when exposed to DPP-4i than those without the HLA gene. The gene could serve as a biomarker to help estimate the risk of developing BP when patients are administered with DPP-4i. The mechanism that connects the HLA gene and BP need to be addressed to help prevent the development of the disease," Ujiie added.
Source: Eurekalert
BP is classified into two types: inflammatory and noninflammatory, the latter of which is found more in diabetic patients administered with the drug. The research team, including Dr. Hideyuki Ujiie of Hokkaido University Hospital, examined 30 BP patients administered with DPP-4i and investigated their symptoms and autoantibodies to group them as inflammatory or noninflammatory.
Diabetes Drug Acetohexamide Repairs UV Damaged DNA in Moon Children
Moonchildren are referred to those with a genetic disorder that can cause inflammation in response to UV rays and can cause skin cancer.
Advertisement
The researchers then analyzed human leukocyte antigen (HLA) genes of the 30 patients to identify their white blood cell type since HLA genes are known to be involved in various immune diseases. To compare, the team also analyzed the HLA of 72 BP patients who had not been administered to DPP-4i and 61 diabetic patients who were using the drug but not affected by BP. Their findings were compared with the HLA genes of 873 Japanese from the general population.
According to the results, 70 percent of the 30 BP patients administered with DPP-4i fell into the noninflammatory type with less reddening of the skin (erythema). HLA analyses found 86 percent of the noninflammatory BP patients administered with DPP-4i had an HLA gene called "HLA-DQB1*03:01."
The rate of having the HLA gene was much higher than was detected among the general population (18 percent) and non-BP type-2 diabetic patients administered with DPP-4i (31 percent). Meanwhile, 26 percent of BP patients who were not administered with the drug had the same HLA gene.
The findings show HLA-DQB1*03:01 is not linked to ordinary BP nor type-2 diabetes, but is closely associated with the development of BP among DPP-4i takers. "However, as the probability of patients exposed to DPP-4i to develop BP remains unclear, further research investigating a much larger number of cases is needed," says Hideyuki Ujiie.
"Our results suggest people with HLA-DQB1*03:01 have a higher risk of developing BP when exposed to DPP-4i than those without the HLA gene. The gene could serve as a biomarker to help estimate the risk of developing BP when patients are administered with DPP-4i. The mechanism that connects the HLA gene and BP need to be addressed to help prevent the development of the disease," Ujiie added.
Source: Eurekalert
Mouthwash Use Increases Diabetes Risk
Regular use of mouthwash for twice every day kills microbes in the mouth that protect the body from diabetes.
Advertisement
 Don't Rule Out Type 1 Diabetes After the Age of thirtyA novel genetic analysis has been done to identify type 1 diabetes in adults, this may help identify type 1 diabetes cases not picked up by doctors. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
